EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Proto‐Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal Cancer

Donghyun Kim iD, Saima Sharif, Juan Antonio Raygoza Garay, Avanish S Bhakta, Patrick M Boland iD, Michael J Cavnar, Michelle L Churchman, Hassan Hatoum, Lyen C Huang iD, Joseph Kim, Richard Kim, Robert W Lentz und 8 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.71114 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Donghyun Kim und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Colorectal Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mutational landscape is prognostic in colorectal cancer (CRC). Rat sarcoma ( RAS ) oncogenes, such as KRAS and NRAS , with driver mutations, portend poor survival outcomes, whereas pathologic mutations in HRAS are extremely rare, and their prognostic value remains uncertain.

Methods

This retrospective study analyzed the Oncology Research Information Exchange Network (ORIEN) alliance tumor RNA‐Seq data in Stages II and III CRC to investigate the association between RAS gene expression and survival outcomes.

Results

High transcript levels of HRAS were associated with superior overall survival (OS). The high HRAS ‐associated OS benefit was most pronounced in patients with right‐sided primary expressing low KRAS transcript levels in the absence of pathologic KRAS mutations.

Conclusions

Contrary to the notion that RAS family genes are proto‐oncogenic, this study demonstrates that high HRAS transcript levels are associated with superior OS in Stages II and III CRC. The potential of HRAS as a prognostic biomarker should be explored further.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)Colorectal NeoplasmsBiomarkers, TumorHumansNeoplasm StagingRetrospective StudiesPrognosisMaleFemaleMutationProto-Oncogene MasMiddle AgedAgedGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

biomarkerscolorectal cancergene expression regulationsurvival

Substanzen

Proto-Oncogene Proteins p21(ras)HRAS protein, humanBiomarkers, TumorProto-Oncogene MasKRAS protein, humanMAS1 protein, human

Autor:innen und Institutionen

  • Division of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA.
  • Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa, USA.
  • Department of Surgery, University of Kentucky, Lexington, Kentucky, USA.
  • Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
  • Department of Clinical & Life Sciences, Aster Insights, Hudson, Florida, USA.
  • Section of Hematology-Oncology, Department of Internal Medicine, University of Oklahoma Health Sciences, Oklahoma City, Oklahoma, USA.

ORCID-Profile: Donghyun Kim, Patrick M Boland, Lyen C Huang

Förderung

  • NCI NIH HHS

Zitieren

APA

Kim, D., Sharif, S., Garay, J. A. R., Bhakta, A. S., Boland, P. M., Cavnar, M. J., Churchman, M. L., Hatoum, H., Huang, L. C., Kim, J., Kim, R., Lentz, R. W., Mukherjee, S., O'Donnell, M. T., Quartey, B., Reilley, M. J., Rounbehler, R. J., Salhia, B., Schneider, B. P., & Chan, C. H. (2025). Proto‐Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.71114

Vancouver

Kim D, Sharif S, Garay JAR, Bhakta AS, Boland PM, Cavnar MJ, et al. Proto‐Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal Cancer. Cancer Medicine. 2025. doi:10.1002/cam4.71114

BibTeX
@article{Kim2025,
  author = {Kim, Donghyun and Sharif, Saima and Garay, Juan Antonio Raygoza and Bhakta, Avanish S and Boland, Patrick M and Cavnar, Michael J and Churchman, Michelle L and Hatoum, Hassan and Huang, Lyen C and Kim, Joseph and Kim, Richard and Lentz, Robert W and Mukherjee, Sarbajit and O'Donnell, Mary T and Quartey, Benjamin and Reilley, Matthew J and Rounbehler, Robert J and Salhia, Bodour and Schneider, Bryan P and Chan, Carlos H},
  title = {Proto‐Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal Cancer},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71114}
}
Kostenlos starten →